ABSTRACT
Introduction Deep learning (DL) models that use medical images to predict clinical outcomes are poised for clinical translation. For tumors that reside in organs that move, however, the impact of motion (i.e. degenerated object appearance or blur) on DL model accuracy remains unclear. We examine the impact of tumor motion on an image-based DL framework that predicts local failure risk after lung stereotactic body radiotherapy (SBRT).
Methods An IRB-approved study (NU00212113) was used to identify patients treated with lung SBRT. Pre-therapy free breathing (FB) CT images from 849 patients were input into a multi-task deep neural network to generate an image fingerprint (or DL score) that predicts time-to-event local failure outcomes. The impact of tumor motion was examined on the DL scores for a hold-out set comprising 228 image series from 19 patients comprising: (1) FB CT, (2) four-dimensional (4D) CT, and (3) maximum-intensity projection (MIP) images.
Findings Variance in image-derived DL scores were associated with tumor motion (R2 = 0.45). Specifically, DL score variance was deterministic with undulations in phase with the respiratory cycle (R2 = 0.77-0.99). DL scores, but not tumor volumes, peaked near end-exhalation (∼50% phase). The mean of the scores derived from 4D CT images and the score obtained from FB CT images were highly associated (Pearson r = 0.99). MIP-derived DL scores were significantly higher than 4D- or FB-derived risk scores (p < 0.0001).
Interpretation We show that an image-based DL risk score derived from a series of four-dimensional CT images varies in a deterministic, sinusoidal trajectory in phase with the respiratory cycle. These results indicate that deep learning models of tumors in motion can be robust to fluctuations in object appearance due to movement and can guide standardization processes in the clinical translation of DL models for patients with lung cancer.
Competing Interest Statement
B.L., A.K., and M.E.A. are named inventors in a patent for the use of Deep Profiler and iGray to personalize radiotherapy dose.
Funding Statement
M.E.A. was supported by NIH R37CA222294, NIH P30CA060553, and the American Lung Association.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
A Northwestern University Institutional Review Board (IRB) approved study (NU00212113) was used to identify 283 patients treated with lung stereotactic body radiotherapy (SBRT) from 2010-2020.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets analyzed during the current study will be available from the corresponding author at the time of publication. Per institutional policy, the datasets are designated limited access. Upon receiving access, the investigator may only use them for the purposes outlined in the request to the data provider and redistribution of the data is prohibited.
